CLINICAL TRIALS AND OBSERVATIONS Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
نویسندگان
چکیده
1Montefiore-Einstein Cancer Center, Montefiore Medical Center, Bronx, NY; 2University of Arkansas for Medical Sciences, Little Rock; 3University of California, San Francisco; 4City of Hope Medical Center, Duarte, CA; 5University of Miami, FL; 6Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD; 7University of California, San Diego and Veterans Affairs San Diego Healthcare System; 8Virginia Mason Cancer Institute, Seattle, WA; 9Memorial Sloan-Kettering Cancer Center, New York, NY; 10Pennsylvania Hospital, Philadelphia; 11Northwestern University, Chicago, IL; 12Beth Israel Deaconess Medical Center, Boston, MA; 13West Virginia University, Morgantown; 14Ohio State University, Columbus; 15Desert Regional Medical Center, Palm Springs, CA; 16Washington University, St Louis, MO; 17Weill Cornell Medical College, New York, NY; and 18UCLA Medical Center, Los Angeles, CA
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS A prospective study of mediastinal gray-zone lymphoma
• MGZL with pathologic features in between NSHL and PMBL is very rare and most frequently occurs in young patients. • A prospective study of DA-EPOCH-R without mediastinal radiation in MGZL demonstrated an inferior outcome compared to patients with PMBL. MediastinalB-cell lymphomaspresent in themediastinumandaremost frequent in young patients. Nodular sclerosis Hodgkin lymphoma (NSHL) and prima...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dosedense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20 diffuse large B-cell lymphoma. Patients received a minimum of 3 and a maximum of 6 cycles with 1 ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma
Idiotype vaccination for follicular lymphoma is primarily being developed as remission consolidation after chemotherapy. We investigated idiotype vaccination as primary intervention for treatmentnaive indolent B-cell lymphoma and in a separate cohort as remission consolidation after chemotherapy to assess immunization-induced immune responses in relation to progression-free survival (German Cli...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Treatment of relapsed CD20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
This phase 2 trial was performed to evaluate the safety and efficacy of the chimeric monoclonal anti-CD20 antibody rituximab in patients with relapsed lymphocyte-predominant Hodgkin lymphoma or other CD20 subtypes of Hodgkin disease (HD). Eligibility criteria required expression of the CD20 antigen on more than 30% of malignant cells. Fourteen patients were treated with 4 weekly intravenous inf...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
Radioimmunotherapy of indolent nonHodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is relatively underused in routine practice. In this article, we report our clinical experience in 142 consecutive patients who received iodine-131 rituximab radioimm...
متن کامل